Company / Cash per Share
Taysha Gene Therapies, Inc. Cash per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$1.56
FY2025
5-year range
$0.74 / $3.96
FY2021-FY2025
Trend
+109.8%
vs FY2024
Sector context
#123 of 205
Health Care
What the data says
At $1.56, Taysha Gene Therapies, Inc.'s cash per share ranks #123 of 205 in the Health Care sector. Cash per Share returned to growth in FY2025 after 4 years of decline, reaching $1.56.
Based on SEC 10-K filings.
1.56 in FY2025 with a 5-year CAGR of -35.7%.
Declined from $2.28 to $1.56 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -11.9%
- 5-Year CAGR
- -35.7%
- 10-Year CAGR
- -
Sector benchmark
#123 of 205 in Health CareTop 60% of 205This company $1.56 Sector average $72.93
▼
-97.9% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 109.8% year-over-year.
- Ranks #123 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2020.
- Lowest cash per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.56 | +109.8% |
| FY2024 | $0.74 | -67.3% |
| FY2023 | $2.28 | -0.3% |
| FY2022 | $2.28 | -42.3% |
| FY2021 | $3.96 | -72.2% |
| FY2020 | $14.22 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026